Drug Trial Radar · NCT03166215
Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Aug 17, 2017
Primary completion
Sep 19, 2018
Study completion Sep 19, 2018
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Healx AI
- First posted
- May 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the multiple-dose safety and tolerability profile of TAK-935 in adult participants with developmental and/or epileptic encephalopathies.
Conditions
- Developmental and/or Epileptic Encephalopathies
Interventions
TAK-935Drug
TAK-935 tablets.
PlaceboDrug
TAK-935 placebo-matching tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the Investigator, After TAK-935 TreatmentTime frame: From first dose up to 30 days post last dose (approximately up to 120 days)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Xenoscience
Phoenix, Arizona
Medsol Clinical Research Center
Port Charlotte, Florida
University of South Florida
Tampa, Florida
Center for Integrative Rare Disease Research
Atlanta, Georgia
Bluegrass Epilepsy Research
Lexington, Kentucky
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
The Comprehensive Epilepsy Care Center for Children and Adults
St Louis, Missouri
Northeast Regional Epilepsy Group
Hackensack, New Jersey
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University of Virginia Health Sciences Center
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.